Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
JSKN003 vs investigator’s choice in HER2-positive metastatic colorectal cancer
CTR20260304Phase 3Active
- Sponsor
- Kanion Pharmaceutical
- Start
- Feb 2026
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of anbenitamab repodatecan in colorectal adenocarcinoma, colorectal cancer (CRC), sponsored by Kanion Pharmaceutical. Started Feb 2026; status: active.
02
Drugs
anbenitamab repodatecan
03
Conditions
colorectal adenocarcinomacolorectal cancer (CRC)
Beyond the preview
Go deeper on CTR20260304.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20260304.